ELIQUIS: Uses, Forms and Safety Reference

ELIQUIS contains apixaban, an anticoagulant with several adult uses and a qualified pediatric clot-treatment indication. The conventional tablets and pediatric suspension presentations have different preparation requirements, while bleeding and interruption risks require careful planning.

The approved uses and formulations described here follow US prescribing information. They may differ in other countries.

Medicine detail Details
Active ingredient(s) apixaban
Medicine class Direct factor Xa inhibitor anticoagulant
Forms and strengths Oral tablets: 2.5 and 5 mg; tablet for oral suspension: 0.5 mg; ELIQUIS SPRINKLE for oral suspension: 0.15 mg per capsule, prepared as directed

Adult uses and the pediatric boundary

The US label covers stroke and systemic-embolism risk reduction in adult nonvalvular atrial fibrillation, adult DVT and pulmonary-embolism treatment and recurrence reduction, and DVT prevention after hip or knee replacement. Pediatric VTE treatment and recurrence reduction require at least five days of initial anticoagulant therapy and label-specific qualifications.

Source: [1]

Tablets and suspension products are distinct

Conventional tablets contain 2.5 or 5 mg. The 0.5 mg tablet for oral suspension and 0.15 mg ELIQUIS SPRINKLE capsules have separate pediatric preparation and weight-based instructions. The capsule contents are prepared as directed rather than treating the capsule as a conventional swallowed dose. Caregivers need the exact product instructions and measuring equipment.

Source: [1]

Bleeding requires prompt assessment

ELIQUIS can cause serious, potentially fatal bleeding and is contraindicated with active pathological bleeding. Uncontrolled bleeding, blood in vomit or stool, significant head injury or other suspected serious blood loss requires urgent assessment. NSAIDs, antiplatelet drugs and other anticoagulants can add to bleeding risk and need a pharmacist's review.

Source: [1]

The boxed warnings affect stopping and procedures

Premature interruption can increase thrombotic events. Spinal or epidural hematomas can occur around neuraxial anesthesia or spinal puncture and can cause paralysis. Tell every treating clinician and dentist about apixaban. The clinical team must plan any interruption, procedure and restart; do not stop solely because an appointment is scheduled.

Source: [1]

Prescribing depends on more than tablet strength

The indication, age, weight, kidney function and interacting medicines can change the regimen. Strong combined P-gp/CYP3A4 inhibitors and inducers require specific review. The label does not recommend use for prosthetic heart valves or triple-positive antiphospholipid syndrome. Another factor Xa inhibitor is not a milligram-for-milligram substitute.

Further reading includes the ELIQUIS and XARELTO comparison. Its selected comparison facts do not provide a switching or dose-conversion plan.

Source: [1]

Questions and answers

Is ELIQUIS SPRINKLE the same as a 5 mg tablet?

No. The pediatric suspension presentations have different strengths, preparation and prescribing instructions.

Should apixaban be stopped before every dental appointment?

Do not decide independently. Tell the dentist and prescribing team so they can plan bleeding and clot-risk management.

Does a lower tablet strength automatically mean lower overall risk?

No. Risk and dose selection depend on the indication, patient factors and interactions, not the tablet number alone.

Related reading

Sources

  1. ELIQUIS: official US prescribing information

Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.

Reviewed by: Mattias Hagman, PhD

About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.

Last reviewed: October 2026